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INTRODUCTION
Despite improvements in short-term renal allograft survival,
the rate of chronic graft loss after the first year has remained
unchanged (1). The leading causes of late allograft loss are
patient death and chronic allograft nephropathy (2). Chron-
ic allograft nephropathy is clinically characterized by a slow
but steady decline in allograft function. It is a highly complex
pathophysiological process, which involves alloantigen and
non-alloantigen dependent factors. Examples of the latter in-
clude hypertension, hyperlipidemia, obesity, metabolic syn-
drome, and proteinuria (2).
Proteinuria is a cardinal manifestation of kidney disease and
is associated with a poor outcome in most renal parenchymal
disorders. It is also generally accepted that one-year post-trans-
plant proteinuria over 0.5 gm per day predicts the develop-
ment of chronic allograft nephropathy and poor graft outcome
(3-5). Therefore, the administration of angiotensin-convert-
ing enzyme inhibitor (ACEI) or angiotensin-receptor blocker
(ARB) is recommended in kidney transplant recipients with
proteinuria exceeding 0.5 g/day (6, 7).
Low levels of proteinuria of less than 0.5 g/day, including
microalbuminuria, have been found to be associated with an
increased risk of chronic kidney disease and cardiovascular
mortality (4, 8) and this has emerged as a useful target for
therapy in subjects with hypertension or diabetes (9). Thus,
we investigated whether proteinuria of less than 0.5 g/day one
year after transplantation is associated with long-term graft
survival.
MATERIALS AND METHODS
Study design and patients
We reviewed all adult recipients who had undergone renal
transplantation in the Samsung Medical Centre between Jan-
uary 1995 and December 1999. During this period, 291 pri-
mary kidney transplantations were performed. Of these, 19
transplantations were excluded due to death (4), graft loss (11),
or being lost to follow-up (4) within one year. Therefore, 272
primary kidney transplant recipients were enrolled in this
study. One-hundred seventy-seven (65.1%) transplants were
cadaveric donor transplants and 95 (34.9%) transplants were
living donor transplants.
Baseline pre-transplant and one-year post-transplant
evaluations
All the patients received a baseline and one-year post-trans-
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Minimal Proteinuria One Year after Transplant is a Risk Factor for
Graft Survival in Kidney Transplantation
It is generally accepted that one-year post-transplant proteinuria over 0.5 gm per day
has a negative impact on renal graft survival. In this study, the effects of minimal pro-
teinuria less than 0.5 g/day were analyzed in 272 renal recipients who had survived
for one year with a functioning graft. Recipients were classified by one-year post-
transplant proteinuria: no proteinuria group (<0.2 g/day), minimal proteinuria group
(0.2-0.5 g/day), and overt proteinuria group (≥ ≥0.5 g/day). Recipients were followed
up for 87.1± ±21 months after transplantation and 38 (13.9%) lost their graft during
follow-up. Fifteen percent of patients had minimal proteinuria and 7.8% had overt
proteinuria. Five-year graft survival in the minimal proteinuria group was 83.0%,
and that in the overt proteinuria group was 70%, in contrast to 97.1% in the no pro-
teinuria group (p=0.01 for trend). In a multivariate analysis, the minimal proteinuria
group (relative risk [RR], 4.90; 95% confidence interval [CI], 2.09-11.46) and the
overt proteinuria group (RR, 8.75; 95% CI, 3.29-23.29) had higher risks of graft fail-
ure than the no proteinuria group. Even minimal proteinuria at one year after trans-
plantation was strongly associated with poor graft outcome. Therefore, it appears
logical to consider a low level of proteinuria as a risk factor for graft survival in renal
recipients.
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Accepted : 12 March 2008plant evaluation according to a standard protocol. Baseline
variables included age, sex, donor age, donor sex, donor type,
duration of pre-transplant maintenance dialysis, and number
of human leukocyte antigen (HLA) mismatches. The presence
or absence of delayed graft function (DGF), and acute rejec-
tion within one year were also recorded. One-year post-trans-
plant variables included systolic and diastolic blood pressure,
post-transplant diabetic mellitus (PTDM), body mass index
(BMI), serum creatinine levels, amount of urinary protein ex-
creted, and medications (anti-hypertensive drugs, including
ACEI and ARB, and immunosuppressants).
Immunosuppressive regimen
Our institution’s immunosuppressive regimen consisted
of calcineurin inhibitor, prednisolone, and azathioprine from
January 1995 to March 1998 or mycophenolate mofetil there-
after. Prednisolone at 1 mg/kg per day was commenced on the
day of transplantation and was gradually tapered to a daily
maintenance dose of 5 mg at six months after transplantation.
The initial dose of cyclosporine was designed to achieve 150-
250 ng/mL trough levels for the first 12 months and 100-
150 ng/mL thereafter. Azathioprine was commenced at 2.5
mg/kg per day or mycophenolate mofetil was commenced
at 1.5 g/day and adjusted subsequently according to the white
blood cell count or significant gastrointestinal side effects.
Definitions and measurements
DGF was defined as the failure of a renal allograft to func-
tion immediately after transplantation and the need for dial-
ysis within one week. Acute rejection was defined when biop-
sy-proven cases received anti-rejection therapy. Hypertension
was defined as a systolic blood pressure of ≥140 mmHg, dias-
tolic blood pressure of ≥90 mmHg, or the use of any anti-
hypertensive drug. Blood pressure was measured in the sit-
ting position after five minutes resting. BMI was calculated
as weight in kilograms divided by height in meters squared
(kg/m
2). PTDM was defined by the symptoms of diabetes plus
a random glucose value of ≥200 mg/dL, a fasting plasma
glucose value of ≥126 mg/dL, or a two-hour plasma glucose
value of ≥200 mg/dL after a 75 g glucose load (10). Eight-
hour fasting blood samples were used to determine glucose
and creatinine levels. Renal allograft function was assessed
by the estimated glomerular filtration rate (GFR), calculat-
ed with the abbreviated Modification of Diet in Renal Dis-
ease (MDRD) Study equation (11, 12). Twenty-four-hour urine
samples were obtained for the determination of urinary pro-
tein excretion. Urinary protein concentrations were measured
using the pyrogallol red-molybdate complex method, which
has a lower detection limit of 1.0 mg/L. Recipients were clas-
sified into one of three groups according to their levels of one-
year post-transplant proteinuria: less than 0.2 g/day as the no
proteinuria group; 0.2-0.5 g/day as the minimal proteinuria
group; and more than 0.5 g/day as the overt proteinuria group.
‘Graft loss’ refers to a return to dialysis or a second transplan-
tation. Graft survival was examined without censoring for death.
Statistical analyses
Statistical analyses were performed using SPSS version 12.0.
Parametric parameters are expressed as means±standard devi-
ations, whereas nonparametric parameters are expressed as
medians (interquartile ranges). To compare means, Student’s
t-test or one-way analysis of variance (ANOVA) was used.
When one-way ANOVA was performed, we used Turkey-B
test as post hoc test. The chi square test or Fischer’s exact test
was used to evaluate the distributions of categorical variables.
Graft survival rates were computed using the Kaplan-Meier
method, and compared using the log-rank test. Cox propor-
tional hazard model was used to identify parameters associ-
ated with graft loss during follow up. All p values reported
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Data are expressed as means±SD, except proteinuria and time on dial-
ysis (expressed as median and interquartile range).
HLA, human leukocyte antigen; BP, blood pressure; PTDM, post-trans-
plant diabetic mellitus; BMI, body mass index; EGFR, estimated glomeru-
lar filtration rate; ACEI, angiotensin-converting enzyme inhibitor; ARB,
angiotensin-receptor blocker; MMF, mycophenolate mofetil.
Variables n=272
Recipient age (yr) 37.8±9.9
Recipient sex, M/F (%) 58/42
Donor age (yr) 32.4±12.4
Donor type, living/cadaver (%) 35/65
Pre-transplant dialysis duration (%)
Pre-emptive/<1 yr/1 yr 3/49/48
Median time on dialysis (months) 12.0 (6.3-24.6)
HLA mismatch number 3.6±1.5
Diabetes mellitus (%) 5.1
Other comorbidities (%)
Ischemic heart disease 1.1
Dilated cardiomyopathy 0.7
History of cerebrovascular disease 0.4
Peripheral arterial occlusive disease 0.7
Chronic viral hepatitis (B or C) 1.5
Delayed graft function (%) 5.1
Acute rejection within 1 yr (%) 22
Systolic BP at 1 yr (mmHg) 130.8±13.4
Diastolic BP at 1 yr (mmHg) 84.5±11.0
PTDM at 1 yr (%) 12.1
BMI (kg/m
2) at 1 yr 22.8±3.0
EGFR (mL/min/1.73 m
2) at 1 yr 62.3±14.4
Proteinuria (mg/day) at 1 yr 118.5 (63.0-192.0)
Use of ACEI/ARB at 1 yr (%) 6.2
No. anti-hypertensive drugs (%)
None/one/two/three or more 26/47/26/1
Immunosuppressants at 1 yr (%)
Cyclosporine/tacrolimus/none 84/15/1
Azathioprine/MMF/none 55/42/3
Table 1. Demographic and transplant characteristics of the
study populationwere considered significant at the 0.05 level.
RESULTS
As outlined in Table 1, 177 (65.1%) transplants were cadav-
eric donor transplants and 95 (34.9%) were living donor trans-
plants. Recipient age and donor age were 37.8±9.9 yr and
32.4±12.4 yr, respectively. One-hundred and fifty-nine (58.4
%) patients were male. The mean number of HLA mismatch-
es was 3.6±1.5. Diabetes mellitus was present in 5.1% of
patients at the time of transplantation. DGF and acute rejec-
tion within one year occurred in 5.0% and 21.3% of recipi-
ents, respectively. Hypertension was detected at one year after
transplantation in 219 (80.9%) recipients, and mean systolic
and diastolic blood pressures were 130.8±13.4 mmHg and
84.5±11.0 mmHg, respectively. PTDM was present in 33
(12.1%) recipients, and mean estimated GFR was 62.3±14.4
mL/min/1.73 m2. Seventeen (6.2%) recipients were treated
with ARB or ACEI. Cyclosporine was used in 84.2% of recip-
ients and tacrolimus in 15.4%; mycophenolate mofetil was
used in 41.5% and azathioprine in 55.1%.
Urinary protein excretion levels were not available for four
patients. Of the remaining 268 patients, 15.7% showed one-
year post-transplant proteinuria of 0.2-0.5 g/day, and 7.8%
had proteinuria of more than 0.5 g/day (Table 2). The mini-
mal and overt proteinuria groups showed a male predomi-
nance. Recipient age, donor age, donor type, number of HLA
mismatches, DGF, acute rejection, blood pressure, and BMI
did not differ between the three groups. Estimated GFR at
the first year was also similar among the three groups. PTDM
was more common in the overt proteinuria group than in
the minimal proteinuria or the no proteinuria group (23.8%,
16.7%, and 10.2%, p=0.043 for trend).
Recipients were followed up for a mean period of 87.1 (13-
130) months after transplantation and 38 (13.9%) recipients
lost their graft during follow-up. Univariate analysis of graft
loss (Table 3) identified the following significant predictors,
the presence of proteinuria, estimated GFR at the first year,
and the use of mycophenolate mofetil. The minimal protein-
uria group (hazard ratio [HR], 3.96; 95% confidence interval
[CI], 1.89-8.30) and the overt proteinuria group (HR, 6.46;
95% CI, 2.87-14.54) were at higher risk of graft loss than the
no proteinuria group. Each 1 mL/min/1.73 m2 increment in
the estimated GFR one year after transplantation decreased
the risk of graft loss (HR, 0.96; 95% CI, 0.93-0.98). The use
of mycophenolate mofetil was associated with a lower risk of
graft loss than the use of azathioprine (HR, 0.41; 95% CI,
0.17-0.95).
Overall five-year graft survival rate was 92% and patients in
the no proteinuria group (five-year graft survival, 97%) pre-
sented with better graft survival than those in the other two
groups. The five-year graft survival in the minimal protein-
uria group was 83%, and that in the overt proteinuria group
was 70%. There was no significant difference between the
minimal and overt proteinuria groups (p=0.272).
Fig. 1 shows the effect of one-year post-transplant protein-
uria on long-term graft survival. The minimal proteinuria
group had poor graft survival than the no proteinuria group
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*, The reference category was proteinuria of <0.2 g/day.
HLA, human leukocyte antigen; DGF, delayed graft function; PTDM,
post-transplant diabetic mellitus; ACEI, angiotensin-converting enzyme
inhibitor; ARB, angiotensin-receptor blocker; EGFR, estimated glomeru-
lar filtration rate; MMF, mycophenolate mofetil; CI, confidence interval.
Hazard ratio 95% CI p
Recipient age (per year) 0.97 0.93-1.00 0.08
Recipient sex (M vs. F) 1.93 0.93-3.98 0.07
Donor age (per year) 1.02 0.99-1.04 0.25
Donor type (cadaver vs. living) 1.10 0.56-2.16 0.76
HLA mismatch number 1.14 0.91-1.42 0.27
DGF (yes vs. no) 1.60 0.49-5.22 0.43
One-year post-transplantation
Acute rejection (yes vs. no) 1.88 0.94-3.73 0.07
Hypertension (yes vs. no) 1.85 0.65-5.24 0.25
PTDM (yes vs. no) 1.61 0.49-5.23 0.43
Use of ACEI/ARB 1.89 0.67-5.34 0.06
Proteinuria (g/day)*
0.2-0.5 3.96 1.89-8.30 0.001
≥0.5 6.46 2.87-14.54 0.001
EGFR (per 1 mL/min/1.73 m
2) 0.96 0.93-0.98 0.002
Use of MMF (vs. azathioprine) 0.41 0.17-0.95 0.04
Table 3. Risk factors for graft loss by univariate analysis
Data are expressed as means±SD.
HLA, human leukocyte antigen; DGF, delayed graft function; BP, blood
pressure; PTDM, post-transplant diabetic mellitus; BMI, body mass
index; ACEI, angiotensin-converting enzyme inhibitor; ARB, aniotensin-
receptor blocker; EGFR, estimated glomerular filtration rate; NS, not sig-
nificant.
Variables
p
One-year post-transplant proteinuria (g/day)
<0.2 0.2-0.5 ≥0.5
(n=205) (n=42) (n=21)
Age (yr) 37.7±9.5 37.4±10.7 39.7±13.1 NS
Sex, M/F (%) 49.8/50.2 88.1/11.9 71.4/28.6 0.001
Donor age (yr) 31.9±12.4 34.2±12.4 33.3±14.1 NS
Donor type, 37.6/62.4 31.0/69.0 19.0/81.0 NS
living/cadaver (%)
HLA mismatch number 3.6±1.6 3.7±1.5 3.7±1.7 NS
DGF (%) 5.4 4.8 4.8 NS
One-year post-transplantation
Acute rejection (%) 19.5 23.8 28.6 NS
Systolic BP (mmHg) 129.8±13.8 134.5±12.7 134.0±9.1 NS
Diastolic BP (mmHg) 83.8±11.0 86.3±10.1 87.9±10.8 NS
PTDM (%) 10.2 16.7 23.8 0.043
BMI (kg/m
2) 22.7±2.9 22.8±2.8 23.3±3.2 NS
Use of ACEI/ARB (%) 4.9 14.3 4.8 NS
EGFR (mL/min/1.73 m
2) 63.0±13.3 61.4±16.8 57.5±20.8 NS
Table 2. Baseline and one-year post-transplant characteristics
according to the amount of urinary protein excretion(five-year graft survival, 83% and 97%, respectively).
The results of multivariate analysis of graft loss (Table 4)
indicated that one-year post-transplant proteinuria was a strong
predictor of graft loss. The overt proteinuria group had a 8.75-
fold higher risk of graft loss (95% CI, 3.29-23.29, p<0.001),
and even the minimal proteinuria group had a 4.90-fold high-
er risk of graft loss than the no proteinuria group after adjust-
ment for the use of mycophenolate mofetil and estimated GFR
at the first year in a continuous fashion (95% CI, 2.09-11.46,
p<0.001).
During the follow-up period, three patients died. One patient
in the minimal proteinuria group died of small bowel infarc-
tion and two in the no proteinuria group died of hepatic fail-
ure and anal cancer.
DISCUSSION
The results of this study indicate that even a low level of
proteinuria (0.2-0.5 g/day) one year after transplantation is
an independent predictor of renal allograft loss. Several stud-
ies have implied that proteinuria is a marker of poor long-term
allograft outcomes (3, 5, 13, 14). A large, single-centre, ret-
rospective study by Roodnat et al. found that proteinuria (mean
1 g/day) increased both the risk of graft failure and the risk
of patient death. Fernandez-Fresnedo et al. (3) showed that
persistent proteinuria of more than 0.5 g/day is an indepen-
dent risk factor for poor allograft outcome and cardiovascu-
lar mortality (4, 5). On the basis of these findings, the Nation-
al Kidney Foundation-Kidney Disease Outcomes Quality
Initiative Guidelines, concluded that the use of ACEI or ARB
in patients with a spot urine total protein/creatinine ratio of
more than 0.5 g/g may have a beneficial effect on graft survival
and mortality (6).
Recently, Halimi et al. brought up the risk of graft loss at
a lower degree of proteinuria level (15, 16). Primarily, microal-
buminuria has been predominantly important not only as a
clinical predictor of progressive renal function but also as a
target of treatment in diabetic and hypertensive kidney dis-
ease for many years (8, 17). It has been suggested that glomeru-
lar hypertension and hyperfiltration are key factors in medi-
ating progressive renal damage, because they have been shown
to predict the development of microalbuminuria in diabetic
and hypertensive kidneys (18, 19). Because renal allograft recipi-
ents have a single kidney, it is presumed that they are exposed
to hyperfiltration before any clinical sign of chronic allograft
nephropathy. Therefore, as seen from our results, it was pre-
dictable that proteinuria of 0.2-0.5 g/day is a risk factor for
graft loss.
Mechanisms by which proteinuria may contribute to declines
in renal function have been recently postulated. Leakage of
protein conferred to proximal tubular epithelial cells has been
shown to promote progression of renal disease by stimulating
cytokines and oxidative stress associated interstitial fibrosis
(20). It has also been argued that the allograft is particularly
vulnerable to the adverse effect of proteinuria by expressing
more major histocompatibility complex II antigen, render-
ing them potentially susceptible to immune reaction (21).
In our study, three patients died. This low mortality rate
might have been due to the relative youthfulness of the recip-
ients and the low proportion of diabetes, and other co morbidi-
ties, because cardiovascular disease is the major cause of death
in renal transplant recipients (22). Proteinuria is generally
accepted as an independent predictor of cardiovascular disease
in renal transplantation (4). However, the lower limit of pro-
teinuria related to patient survival has not been determined.
We could not assess the association between a low level of pro-
teinuria and patient survival because of the low mortality rate.
Proteinuria of more than 0.5 g/day was found in 7.8% of
our study subjects, which is lower than that previously report-
ed (3, 5, 15). Several studies have suggested that post-trans-
plantation proteinuria is the consequence of many factors, in-
cluding pre-transplant renal lesions, ischemia-reperfusion injury,
and immunological aggression (15). Thus, the low prevalence
of proteinuria in this study might be attributable to donor
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This model also includes sex, age, donor age, donor type, HLA mismatch
number, delayed graft function, acute rejection within one year, systolic
blood pressure, post-transplant diabetic mellitus, and use of ACEI/ARB.
*, The reference category was proteinuria of ≤0.2 g/day.
CI, confidence interval; EGFR, estimated glomerular filtration rate; MMF,
mycophenolate mofetil.
Relative risk (95% CI) p
Proteinuria (g/day)*
0.2-0.5 4.90 (2.09-11.46) <0.001
≥0.5 8.75 (3.29-23.29) <0.001
EGFR (per mL/min/1.73 m
2) 0.95 (0.92-0.97) <0.001
Use of MMF (vs. azathioprine) 0.23 (0.08-0.60) 0.003
Table 4. Multivariate-adjusted relative risks of graft loss
Fig. 1. Effect of one-year post-transplant proteinuria on long-term
graft survival. The minimal proteinuria group showed poor graft sur-
vival than the no proteinuria group. Log-rank test: p<0.01.
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Months after transplantationand recipient ages and the low incidence of DGF and acute
rejection.
Some limitations of our study should be noted. First, our
study participants were not representative general renal recip-
ients. Our subjects were relatively young, had a low preva-
lence of diabetes and other comorbidities. And more than
50% of them spent less than 1 yr on dialysis prior to trans-
plantation. Although these characteristics limit the general-
izability of our finding, it suggests that even a small amount
of proteinuria should be worth paying attention in kidney
transplants with a low risk profile. Second, we used a single
24-hr urine sample to evaluate proteinuria. The disadvan-
tages of 24-hr urine samples are their inconvenience and
potential inaccuracy. However, the patients were trained in
the proper method for collection in this study, and 24-hr
urine collection is still recommended for the definitive mea-
surement of urinary protein excretion in renal recipients (23).
Third, it was unclear whether the origin of the proteinuria
was glomerular or tubular. These two forms of proteinuria
are induced by different mechanisms and thus may have
different prognostic significance. An analysis of the correla-
tion between proteinuria and allograft pathology should be
conducted to clarify the role of proteinuria (2). Fourth, few
patients received ACEI or ARB, so the effects of both drugs
could not be evaluated. The use of ACEI and ARB is becom-
ing increasingly common in treating hypertension in renal
recipients, but it has been discouraged in the early post-trans-
plantation period, because it may compromise effective allo-
graft blood flow in renal artery stenosis or in recipients with
calcineurin-induced vasoconstriction.
In conclusion, we have demonstrated that minimal pro-
teinuria one year after transplantation is associated with poor
allograft outcomes as in recent studies. This association has
an additive value in terms of being able to apply to the patient
groups with low risk profile. Therefore, it seems logical to
consider minimal proteinuria as a predictor for graft survival
in renal transplant recipients. These findings provide a ratio-
nale for prospective studies that aim to verify whether anti-
proteinuric therapy can prolong graft survival in recipients
with minimal proteinuria.
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